We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Phosphagen. | PSG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.25 | 2.25 |
| Top Posts |
|---|
Posted at 17/7/2009 21:53 by newbi55 There are a number of threads on PSG (POH on ASX) on an Australian Investment Network at Worth a look to read other opinions (from an Australian Investors point of view)about this company and it's free to sign up. Can anyone tell me the best way to trade these shares from here in the UK? Recommend a broker perhaps. |
Posted at 19/6/2009 11:15 by ladybird1 LGW- Try going in via the ASX (australian stock exchange) website & search for their acronym 'POH' (the ASX equivalent of the PSG here). The anouncement is given there - The website is not being very actively maintained. I queried it & understand Mary Mcswiggan, who looks after it, is on maternity leave. Understandably I think, given the size of the staff, the website has not been a priority. - That said, I am registered for email news updates (which you regiser for via the website) & received one this morning. I assume this tie-up is the one flagged in the AGM address (also available on the ASX website). Good Luck |
Posted at 19/6/2009 09:05 by lgw 25% increase in share price today, must go and do some more psg research as the why. |
Posted at 11/6/2009 08:59 by lgw Nice rise today, my holding in PSG is still in my TD Waterhouse statement but listed on Aussie exchange. I did not have to do anything they transferred it automatically, have not tried to trade it mind you. |
Posted at 15/5/2009 10:43 by ladybird1 serratia I think I used a wrong term. I just meant the listing you get for recent posts in time order by presing 'Free BB'. I clicked it last night just after a post to PSG, which of course I was surprised to see. |
Posted at 30/9/2008 09:24 by donaferentes They should have emailed you that there is a message on S/trade re PSG which does not say much more than above (in fact rather less). They have not decided how to deal with the issue yet and will announce later. I plan to start badgering them for an answer from the beginning of the 2nd week in October - the 8th. |
Posted at 08/7/2008 11:45 by lgw Agree with donaf I put this into a Sipp last year so well down, but not fussed terribly because I have another 15yrs before cashing in, will add on the dips also but maybe not this month!Everything seems to be going into place here, I think parts or all of PSG will eventually be taken over as the potential product potential is superb, and getting closer to fruition. Re Michael Ashton, is he well respected? I know he is well known but what is his previous form, it would seem too fortuitous for tiny little PSG to have such a high profile businessman as a director! |
Posted at 07/5/2008 07:48 by hopeless698 07 May 2008Company Announcement Phosphagenics Completes A$9.1 M Capital Raising Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that it has raised A$9.1 m via a placement of approximately 60.6 million fully paid ordinary shares to leading overseas and domestic institutions, and other sophisticated investors, at 15 cents per share. It is expected that trading in the new shares on the Australian Stock Exchange will commence on or around 12 May 2008. Mr Harry Rosen, Phosphagenics' President & CEO said that the company was very pleased with the response from investors. "We are very pleased to receive this substantial support from our existing shareholders as we continue to focus on the discovery of new and cost-effective ways to enhance the bioavailability, delivery, efficacy and safety of proven pharmaceutical and nutraceutical products," Mr Rosen said. "The funds raised considerably strengthen the Company's financial position and together with government grants and other revenue will support Phosphagenics' research and development programs through to the end of calendar year 2009," he said. Attached for release to the market is an Appendix 3B notice together with a Section 708A notice. ENDS....... APPENDIX AND NOTES TO EDITORS About Phosphagenics Limited Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, efficacy and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms. |
Posted at 30/4/2008 07:24 by hopeless698 Pre-Clinical Trial ResultsRNS Number:4072T Phosphagenics Limited 30 April 2008 30 April 2008 Company Announcement Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine - Company's TPM Drug Delivery Technology Demonstrates Substantial Increase in Lidocaine Penetration Compared to a Leading Marketed Product - Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced positive results of a pre-clinical study using TPM, the Company's patented drug deliver system, for the targeted delivery of lidocaine, demonstrating increased efficacy while restricting systemic exposure. A phase 1 human clinical trial is scheduled to commence in the third quarter of 2008. Study Design The study was designed to demonstrate the ability of TPM to deliver lidocaine (5%) to a targeted local site after a single topical application, while restricting systemic exposure. Lidocaine concentrations were measured in the skin at the site of application as well as in the underlying muscle and tissue. The studies were performed in parallel using a leading commercial form of lidocaine, Xylocaine(R) 5%, to assess the relative efficacy of the TPM/Lidocaine formulation. TPM/Lidocaine or Xylocaine(R) (20microgram) were applied to a 2x2 cm2 area of shaved skin on the thigh of the treatment, or control animals (n=10). Blood samples were taken at 0 (before application), 1, 2, 3, and 5 hours after application. Lidocaine concentrations were measured in the skin at the site of application as well as in the underlying muscle to determine the amount of lidocaine delivered to the local area of application. Plasma lidocaine concentration was quantified to evaluate systemic exposure. Study Results Phosphagenics' TPM/Lidocaine increased, by a statistically significant margin (p London Stock Exchange's Alternative Investment Market (PSG). An ADR - Level 1 program was established in the U.S. with The Bank of New York Mellon (PPGNY) for U.S. investors to trade in Phosphagenics' stock on the 'over-the-counter' market. In July 2007, this was upgraded to the International OTCQX, a new premium market tier in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC. For more information, please visit Phosphagenics' web site at www.phosphagenics.co Safe Harbor Statement This press release contains forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialise, actual results could vary materially from the Phosphagenics' expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations. Company Contact Details: U.S. Investor and Media Contacts: Esra Ogru Brian Ritchie Phosphagenics Limited Financial Dynamics Executive VP R&D +1 212 850 5683 +61 3 9605 5900 Mary McSwiggan Phosphagenics Limited Investor Relations Manager +61 3 9605 5907 |
Posted at 22/4/2008 09:01 by donaferentes Here's the link- sorry copy and paste - forgotten how to make it a true link.Excellence_in_Biotec still making steady progress without discernible fault. patience required PS: can anyone confirm PSG is ISAable, although AIM it is listed on Aus market and dealt with in US?? TIA |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
